MIRA Pharmaceuticals, Inc. Debt Issuance Costs, Net
MIRA Pharmaceuticals, Inc. (MIRA) had Debt Issuance Costs, Net of $2.78 million as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes
us-gaap:DeferredFinanceCostsNet · last filed 2023-11-13
- 2023-09-30: Debt Issuance Costs, Net $2.78M.
- 2023-06-30: Debt Issuance Costs, Net $3.22M.
| Period end | Debt Issuance Costs, Net |
|---|---|
| 2023-09-30 | $2.78M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $3.22M 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |